PRSS1 and hereditary chronic pancreatitis: Joergensen et al. [27] found that from 2006 to 2014, annual surveillance with EUS was cost-effective at a WTP of $50,000/QALY among a real-world cohort with FPC kindreds (baseline age > 50) but not in individuals with a PRSS1 PGV or hereditary pancreatitis kindreds (baseline age > 30), noting that for the latter group, the analysis would influence their future prospective cohorts to begin at a baseline age of 40.